Differential Effects of IGF-I and Insulin on Glucoregulation and Fat Metabolism in Depancreatized Dogs

The effects of equipotent glucose-lowering doses of insulinlike growth factor I (IGF-I) and insulin on tracer-determined glucose kinetics and several metabolites were compared in 14 experiments (7 in each group) in fasted, totally depancreatized dogs. This model prevented variations in insulin secretion induced by IGF-I and permitted evaluation of the effects of IGF-I on extrapancreatic glucagon. Steady-state moderate hyperglycemia (9.9 ± 0.2 mM) was maintained by a subbasal intraportal infusion of insulin (1.29 ± 0.17 pmol · kg−1 · min−1). This was continued throughout the experiment, allowing evaluation of IGF-I effects on insulin clearance. Human recombinant IGF-I or insulin was given intravenously as a primed infusion for 90 min, followed by a 50-min recovery period. The dose of IGF-I was a 2.6-nmol/kg bolus plus 57.4 pmol · kg−1 · min−1. The insulin dose required to induce the same plasma glucose decline as IGF-I (44 ± 6 vs. 43 ± 5%, NS) was 9–12 times lower (0.06-nmol/kg bolus + 6.4 ± 0.6 pmol · kg−1 · min−1). However, the mechanism of this decline differed with IGF-I and insulin; glucose production was much less suppressed (25 ± 9 vs. 42 ± 11%, P < 0.001) and glucose utilization was more stimulated (68 ± 18 vs. 38 ± 19%, P < 0.05) with IGF-I. Lactate and pyruvate increased significantly with IGF-I (by 85 ± 28 and 123 ± 83%, respectively) but not with insulin. Glycerol and free-fatty acid levels decreased much less with IGF-I than insulin (29 ± 16 vs. 52 ± 5%, P < 0.05, and 36 ± 10 vs. 56 ± 8%, P < 0.01). β-Hydroxybutyrate, alanine, and glucagon decreased similarly with IGF-I or insulin by 60, 20, and 20%, respectively. Plasma insulin was not affected by IGF-I administration (92.6 ± 8.5 vs. 92.6 ± 10.1 pM). In conclusion, in insulin-infused depancreatized dogs, 1) IGF-I is 8–11% as potent as insulin as a glucose-lowering agent on a molar basis, 2) IGF-I does not affect insulin clearance at doses effective in lowering plasma glucose, and 3) equipotent glucose-lowering doses of IGF-I and insulin have very different effects on both glucose kinetics and lipolysis. This suggests that the IGF-I-insulin potency ratio in vivo is higher in muscle than liver or adipose tissue. Therefore, insulinlike effects of supraphysiological doses of IGF-I can be mediated not only through the insulin but also the IGF-I receptor.

[1]  R. Sherwin,et al.  Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. Comparison with insulin. , 1989, The Journal of clinical investigation.

[2]  K. Hall,et al.  Serum levels of insulin‐like growth factor (IGF) I, II and IGF binding protein in diabetic adolescents treated with continuous subcutaneous insulin infusion , 1989, Journal of internal medicine.

[3]  R. Rizza,et al.  Underestimation of Glucose Turnover Measured With [6-3H]- and [6,6-2 H2]- but not [6-14C]glucose During Hyperinsulinemia in Humans , 1989, Diabetes.

[4]  R. Bergman,et al.  Modeling Error and Apparent Isotope Discrimination Confound Estimation of Endogenous Glucose Production During Euglycemic Glucose Clamps , 1988, Diabetes.

[5]  D. James,et al.  Insulin‐like growth factor I binding and receptor kinase in red and white muscle , 1988, FEBS letters.

[6]  D. Wasserman,et al.  Regulation of glucose turnover during exercise in pancreatectomized, totally insulin-deficient dogs. Effects of beta-adrenergic blockade. , 1988, The Journal of clinical investigation.

[7]  J. Poulos,et al.  Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. , 1988, The Journal of clinical investigation.

[8]  P. Arner,et al.  Studies of acute effects of insulin-like growth factors I and II in human fat cells. , 1987, The Journal of clinical endocrinology and metabolism.

[9]  A. Cherrington,et al.  Effect of somatostatin on nonesterified fatty acid levels modifies glucose homeostasis during fasting. , 1987, The American journal of physiology.

[10]  R N Bergman,et al.  Estimation of Endogenous Glucose Production During Hyperinsulinemic-Euglycemic Glucose Clamps: Comparison of Unlabeled and Labeled Exogenous Glucose Infusates , 1987, Diabetes.

[11]  E. Froesch,et al.  Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. , 1987, The New England journal of medicine.

[12]  C Cobelli,et al.  Non-steady state: error analysis of Steele's model and developments for glucose kinetics. , 1987, The American journal of physiology.

[13]  R. Baxter,et al.  Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma. , 1986, The Journal of clinical investigation.

[14]  P. Lönnroth,et al.  Specific binding of human growth hormone but not insulin‐like growth factors by human adipocytes , 1986, FEBS letters.

[15]  E. Froesch,et al.  Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. , 1986, The Journal of clinical investigation.

[16]  E. Froesch,et al.  Insulin-like growth factor I and growth hormone in canine starvation. , 1985, Acta endocrinologica.

[17]  D. Wasserman,et al.  Interactions between glucagon and other counterregulatory hormones during normoglycemic and hypoglycemic exercise in dogs. , 1984, The Journal of clinical investigation.

[18]  R. Bergman,et al.  Extrapancreatic effect of somatostatin infusion to increase glucose clearance. , 1984, The American journal of physiology.

[19]  Y. Marchand-Brustel,et al.  Insulin and Insulin-like Growth Factor I: Effects on Protein Synthesis in Isolated Muscles from Lean and Goldthioglucose-Obese Mice , 1983, Diabetes.

[20]  R. DeFronzo,et al.  Regulation of Splanchnic and Peripheral Glucose Uptake by Insulin and Hyperglycemia in Man , 1983, Diabetes.

[21]  Z. Laron,et al.  Serum levels of insulin-like growth factor (IGF) and its carrier protein in various metabolic disorders. , 1980, Acta endocrinologica.

[22]  M. Vranic,et al.  Physiologic Effects of Epinephrine on Glucose Turnover and Plasma Free Fatty Acid Concentrations Mediated Independently of Glucagon , 1980, Diabetes.

[23]  Y. Le Marchand-Brustel,et al.  Effects and binding of insulin-like growth factor I in the isolated soleus muscle of lean and obese mice: comparison with insulin. , 1979, Endocrinology.

[24]  M. Prentki,et al.  Identical biological effects of pancreatic glucagon and a purified moiety of canine gastric immunoreactive glucagon. , 1979, The Journal of clinical investigation.

[25]  E. Schoenle,et al.  Insulin-like growth factors I and II: some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulin-like activity of human serum. , 1978, European journal of biochemistry.

[26]  E. Froesch,et al.  Decrease of non-suppressible insulin-like activity after pancreatectomy and normalization by insulin therapy. , 1977, Acta endocrinologica.

[27]  Jennings,et al.  The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog. , 1976, The Journal of clinical investigation.

[28]  M. Vranic,et al.  The essentiality of insulin and the role of glucagon in regulating glucose utilization and production during strenuous exercise in dogs. , 1976, The Journal of clinical investigation.

[29]  J. McGarry,et al.  The regulation of ketogenesis from octanoic acid. The role of the tricarboxylic acid cycle and fatty acid synthesis. , 1971, The Journal of biological chemistry.

[30]  K. Sussman.  Effect of Prolonged Fasting Glucose and Insulin Metabolism in Exogenous Obesity , 1966 .

[31]  M. Vranic,et al.  Glucoregulation in alloxan-diabetic dogs. , 1986, Metabolism: clinical and experimental.

[32]  E. Schoenle,et al.  Effect of trypsin treatment of rat adipocytes on biological effects and binding of insulin and insulin-like growth factors: further evidence for the action of insulin-like growth factors through the insulin receptor. , 1981, European journal of biochemistry.

[33]  R. Steele,et al.  ON THE HORMONAL REGULATION OF CARBOHYDRATE METABOLISM; STUDIES WITH C14 GLUCOSE. , 1963, Recent progress in hormone research.